JP2013516984A - 試料中の異常核酸の増幅を確実にするための方法 - Google Patents
試料中の異常核酸の増幅を確実にするための方法 Download PDFInfo
- Publication number
- JP2013516984A JP2013516984A JP2012548931A JP2012548931A JP2013516984A JP 2013516984 A JP2013516984 A JP 2013516984A JP 2012548931 A JP2012548931 A JP 2012548931A JP 2012548931 A JP2012548931 A JP 2012548931A JP 2013516984 A JP2013516984 A JP 2013516984A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sample
- abnormal
- amplification
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 137
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 136
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title claims abstract description 85
- 230000003321 amplification Effects 0.000 title claims abstract description 47
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 47
- 230000002159 abnormal effect Effects 0.000 title claims abstract description 39
- 238000006243 chemical reaction Methods 0.000 claims abstract description 36
- 238000004445 quantitative analysis Methods 0.000 claims abstract description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 31
- 238000003753 real-time PCR Methods 0.000 claims description 21
- 210000001124 body fluid Anatomy 0.000 claims description 17
- 239000010839 body fluid Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 210000003739 neck Anatomy 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 210000004100 adrenal gland Anatomy 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000003238 esophagus Anatomy 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 210000001215 vagina Anatomy 0.000 claims description 3
- 206010003445 Ascites Diseases 0.000 claims 3
- 210000003567 ascitic fluid Anatomy 0.000 claims 3
- 210000003756 cervix mucus Anatomy 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 210000002751 lymph Anatomy 0.000 claims 3
- 210000003097 mucus Anatomy 0.000 claims 3
- 210000002381 plasma Anatomy 0.000 claims 3
- 210000003296 saliva Anatomy 0.000 claims 3
- 210000000582 semen Anatomy 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000000523 sample Substances 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 34
- 239000013615 primer Substances 0.000 description 16
- 230000035772 mutation Effects 0.000 description 14
- 239000000975 dye Substances 0.000 description 12
- 238000007834 ligase chain reaction Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000005382 thermal cycling Methods 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/689,597 | 2010-01-19 | ||
| US12/689,597 US20110177512A1 (en) | 2010-01-19 | 2010-01-19 | Method for assuring amplification of an abnormal nucleic acid in a sample |
| PCT/US2010/050195 WO2011090517A1 (en) | 2010-01-19 | 2010-09-24 | Method for assuring amplification of an abnormal nucleic acid in a sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516984A true JP2013516984A (ja) | 2013-05-16 |
| JP2013516984A5 JP2013516984A5 (https=) | 2013-11-07 |
Family
ID=44277844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548931A Pending JP2013516984A (ja) | 2010-01-19 | 2010-09-24 | 試料中の異常核酸の増幅を確実にするための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110177512A1 (https=) |
| EP (1) | EP2526202A4 (https=) |
| JP (1) | JP2013516984A (https=) |
| WO (1) | WO2011090517A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016540508A (ja) * | 2013-12-02 | 2016-12-28 | バイオカーティス エヌ ヴイ | 循環核酸の抽出 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1712639B1 (en) | 2005-04-06 | 2008-08-27 | Maurice Stroun | Method for the diagnosis of cancer by detecting circulating DNA and RNA |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| GB2533006B (en) | 2012-09-04 | 2017-06-07 | Guardant Health Inc | Systems and methods to detect copy number variation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| ES2660989T3 (es) | 2013-12-28 | 2018-03-27 | Guardant Health, Inc. | Métodos y sistemas para detectar variantes genéticas |
| WO2017106768A1 (en) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Methods to determine tumor gene copy number by analysis of cell-free dna |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952170A (en) * | 1993-12-16 | 1999-09-14 | Stroun; Maurice | Method for diagnosing cancers |
| US20090234621A1 (en) * | 2004-12-03 | 2009-09-17 | Forensic Science Service Limited | Method of optimizing parameters in the entire process of analysing a dna containing sample and method of modeling said process |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5994056A (en) * | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| US5567583A (en) * | 1991-12-16 | 1996-10-22 | Biotronics Corporation | Methods for reducing non-specific priming in DNA detection |
| US5348853A (en) * | 1991-12-16 | 1994-09-20 | Biotronics Corporation | Method for reducing non-specific priming in DNA amplification |
| US6033854A (en) * | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
| US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
| EP1033411B1 (en) * | 1996-06-04 | 2006-02-22 | University of Utah Research Foundation | Fluorescent donor-acceptor pair |
| US6117635A (en) * | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
| US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
| US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
| US5989823A (en) * | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
| GB9812768D0 (en) * | 1998-06-13 | 1998-08-12 | Zeneca Ltd | Methods |
| DE19935772C2 (de) * | 1999-07-26 | 2002-11-07 | Epigenomics Ag | Verfahren zur relativen Quantifizierung der Methylierung von Cytosin Basen in DNA-Proben |
| WO2008103770A2 (en) * | 2007-02-20 | 2008-08-28 | Applera Corporation | Multiplex compositions and methods for quantification of human nuclear dna and human male dna and detection of pcr inhibitors |
| JP2010528585A (ja) * | 2007-02-26 | 2010-08-26 | ジョン ウェイン キャンサー インスティテュート | 癌の診断および治療におけるｂ−ｒａｆｄｎａ変異の有用性 |
| US20090203015A1 (en) * | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
-
2010
- 2010-01-19 US US12/689,597 patent/US20110177512A1/en not_active Abandoned
- 2010-09-24 JP JP2012548931A patent/JP2013516984A/ja active Pending
- 2010-09-24 WO PCT/US2010/050195 patent/WO2011090517A1/en not_active Ceased
- 2010-09-24 EP EP10844135.3A patent/EP2526202A4/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952170A (en) * | 1993-12-16 | 1999-09-14 | Stroun; Maurice | Method for diagnosing cancers |
| US20090234621A1 (en) * | 2004-12-03 | 2009-09-17 | Forensic Science Service Limited | Method of optimizing parameters in the entire process of analysing a dna containing sample and method of modeling said process |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016540508A (ja) * | 2013-12-02 | 2016-12-28 | バイオカーティス エヌ ヴイ | 循環核酸の抽出 |
| US10385330B2 (en) | 2013-12-02 | 2019-08-20 | Biocartis N.V. | Extraction of circulating nucleic acids |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011090517A1 (en) | 2011-07-28 |
| EP2526202A1 (en) | 2012-11-28 |
| EP2526202A4 (en) | 2013-07-31 |
| US20110177512A1 (en) | 2011-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5531367B2 (ja) | 標的配列の濃縮 | |
| Marras et al. | Real-time assays with molecular beacons and other fluorescent nucleic acid hybridization probes | |
| JP6664381B2 (ja) | 核酸アッセイにおける改善された融解識別と多重化のためのプローブ | |
| US20240301483A1 (en) | Dna mutation detection employing enrichment of mutant polynucleotide sequences and minimally invasive sampling | |
| CN101680029B (zh) | 核酸检测 | |
| CN101381766B (zh) | 一种基因稀有突变的定量检测方法 | |
| JP3844996B2 (ja) | 反復性ｐｃｒ産物の融解曲線解析方法 | |
| JP2013516984A (ja) | 試料中の異常核酸の増幅を確実にするための方法 | |
| ES2538214T3 (es) | Un método para el análisis de metilación de ácido nucleico | |
| DK2412718T3 (en) | CIRCUIT PRIMES USED BY NUCLEIC ACID AMPLIFICATION AND USE THEREOF | |
| KR102371222B1 (ko) | 표적핵산 증폭방법 및 표적핵산 증폭용 조성물 | |
| KR102814480B1 (ko) | 표적 핵산을 검출하기 위한 루프형 프라이머 및 루프-드-루프 방법 | |
| US20140274779A1 (en) | Multiplex allele detection | |
| JP2003534812A (ja) | 制限プライマー伸長によるヌクレオチド配列変異の検出 | |
| JP5593582B2 (ja) | 核酸の迅速な検出方法 | |
| Liang et al. | A novel fluorescence method based on loop-mediated isothermal amplification and universal molecular beacon in Mycobacterium tuberculosis detection | |
| EP3055430B1 (en) | Method for the detection of target nucleic acid sequences | |
| JP2003518951A (ja) | 多型核酸配列の同時増幅およびリアルタイム検出のための方法 | |
| WO2011006306A1 (zh) | 锁核酸和小沟结合物共修饰的核酸片段 | |
| JP2024523655A (ja) | 核酸分析のための方法および組成物 | |
| Overbergh et al. | Quantitative Polymerase Chain Reaction | |
| KR20220071536A (ko) | 높은 특이도의 표적핵산 증폭방법 및 이를 이용한 표적핵산 증폭용 조성물 | |
| Devi et al. | Real Time PCR as a Diagnostic Tool in Biomedical Sciences | |
| JP7815296B2 (ja) | 核酸の増幅のための試薬、混合物、キット、および方法 | |
| KR102840216B1 (ko) | 말 호흡기 질병 동시 감별진단용 키트 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130920 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150521 |